Expanding japanese encephalitis vaccination to selected endemic indonesia provinces: A cost-effectiveness analysis.

Cost-effectiveness Expanding JE vaccination Indonesia Japanese encephalitis

Journal

Vaccine: X
ISSN: 2590-1362
Titre abrégé: Vaccine X
Pays: England
ID NLM: 101748769

Informations de publication

Date de publication:
Aug 2022
Historique:
received: 12 08 2021
revised: 29 05 2022
accepted: 31 05 2022
entrez: 5 7 2022
pubmed: 6 7 2022
medline: 6 7 2022
Statut: epublish

Résumé

A Markov model was used to evaluate the potential health and economic impact of introducing JE vaccine nationally and in selected endemic areas of Indonesia compared to no vaccination from government and societal perspectives over a child's lifetime horizon. Costs were obtained from hospitalized JE suspected patient billing data from 2014 to 2019 in seven provinces. Local data burden data were derived from the literature. Analysis considered several scenarios, including national and sub-regional introduction in seven provinces via a one-time vaccination campaign in all children 1-15 years old followed by routine immunization among infants (RI), or RI alone without vaccination campaign. Across scenarios, JE vaccination was projected to range from cost-saving to cost-effective compared to no vaccination at a willingness-to-pay threshold of 0.5x gross domestic product per capita. Including a one-time campaign would avert nearly three times as many JE cases and deaths compared to RI alone while still providing good value for money.

Identifiants

pubmed: 35782720
doi: 10.1016/j.jvacx.2022.100179
pii: S2590-1362(22)00039-0
pmc: PMC9243152
doi:

Types de publication

Journal Article

Langues

eng

Pagination

100179

Informations de copyright

© 2022 The Authors.

Déclaration de conflit d'intérêts

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

Bull World Health Organ. 2016 Dec 1;94(12):925-930
pubmed: 27994285
Lancet Glob Health. 2015 Nov;3(11):e712-23
pubmed: 26475018
Bull World Health Organ. 2015 Feb 1;93(2):118-24
pubmed: 25883405
Vaccine. 2012 Aug 10;30(37):5569-77
pubmed: 22698453
Wkly Epidemiol Rec. 2015 Feb 27;90(9):69-87
pubmed: 25726573
Bull World Health Organ. 2003;81(5):334-42
pubmed: 12856051
Vaccine. 2010 Jun 23;28(29):4593-9
pubmed: 20470803
Vaccine. 2020 Mar 17;38(13):2833-2840
pubmed: 32085954
Bull World Health Organ. 2011 Oct 1;89(10):766-74, 774A-774E
pubmed: 22084515
Am J Trop Med Hyg. 2008 Dec;79(6):963-70
pubmed: 19052312
Hum Vaccin Immunother. 2014;10(12):3579-93
pubmed: 25668666
Prog Neurobiol. 2010 Jun;91(2):108-20
pubmed: 20132860
Vaccine. 2008 Aug 18;26(35):4456-60
pubmed: 18602436
Value Health. 2016 Dec;19(8):929-935
pubmed: 27987642
Value Health. 2018 Jul;21(7):759-761
pubmed: 30005746
Acta Trop. 2018 Nov;187:240-247
pubmed: 30118700
BMC Med. 2006 Apr 07;4:8
pubmed: 16603053
Int J Infect Dis. 2009 Nov;13(6):e389-93
pubmed: 19346144

Auteurs

Soewarta Kosen (S)

Health Systems Specialist, Taman Kebon Jeruk W4 No. 34, Jakarta 11630, Indonesia.

Levina Chandra Khoe (LC)

Department of Community Medicine, School of Medicine University of Indonesia, Indonesia.

Endang Indriasih (E)

National Institute of Health Research & Development, Ministry of Health, Indonesia.

Ingan Tarigan (I)

National Institute of Health Research & Development, Ministry of Health, Indonesia.

Retno Widyastuti Iriawan (RW)

National Institute of Health Research & Development, Ministry of Health, Indonesia.

Rozana Ika Agustiya (RI)

National Institute of Health Research & Development, Ministry of Health, Indonesia.

G William Letson (GW)

Program Appropriate Technology for Health (PATH), Seattle, USA.

Elisabeth Vodicka (E)

Program Appropriate Technology for Health (PATH), Seattle, USA.

Classifications MeSH